PharmaCell to Purchase Cell Therapy Production Facility from TiGenix
PTSM: Pharmaceutical Technology Sourcing and Management
PharmaCell enters an agreement purchase TiGenix therapy production facility.
PharmaCell B.V., a CMO for cellular therapies and regenerative medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its therapy production facility at the Chemelot site in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product for cartilage repair, ChondroCelect. TiGenix and PharmaCell have signed an agreement to purchase the shares of TiGenix B.V., which holds the manufacturing site, subject to certain closing conditions and intend to close the transaction in the coming months. PharmaCell will acquire the facility, including its employees in Production, QC, QA and other functions. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with PharmaCell.
Source: PharmaCell B.V.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
